AU2019355062B2 - Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use - Google Patents

Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use

Info

Publication number
AU2019355062B2
AU2019355062B2 AU2019355062A AU2019355062A AU2019355062B2 AU 2019355062 B2 AU2019355062 B2 AU 2019355062B2 AU 2019355062 A AU2019355062 A AU 2019355062A AU 2019355062 A AU2019355062 A AU 2019355062A AU 2019355062 B2 AU2019355062 B2 AU 2019355062B2
Authority
AU
Australia
Prior art keywords
dral
domain
seq
peptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019355062A
Other languages
English (en)
Other versions
AU2019355062A1 (en
Inventor
Roberto MEZA-ROMERO
Halina Offner
Arthur Vandenbark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Publication of AU2019355062A1 publication Critical patent/AU2019355062A1/en
Application granted granted Critical
Publication of AU2019355062B2 publication Critical patent/AU2019355062B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019355062A 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use Active AU2019355062B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741941P 2018-10-05 2018-10-05
US62/741,941 2018-10-05
PCT/US2019/054850 WO2020072992A1 (en) 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use

Publications (2)

Publication Number Publication Date
AU2019355062A1 AU2019355062A1 (en) 2021-05-06
AU2019355062B2 true AU2019355062B2 (en) 2025-12-18

Family

ID=68296863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019355062A Active AU2019355062B2 (en) 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use

Country Status (8)

Country Link
US (1) US11945855B2 (https=)
EP (1) EP3860644A1 (https=)
JP (1) JP7511551B2 (https=)
KR (1) KR102925681B1 (https=)
CN (1) CN113164573B (https=)
AU (1) AU2019355062B2 (https=)
CA (1) CA3114446A1 (https=)
WO (1) WO2020072992A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719466A1 (en) * 2023-05-26 2026-04-08 Oregon Health & Science University Treatment of cancer with drq polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US20150098956A1 (en) * 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS
US20180271935A1 (en) * 2017-03-15 2018-09-27 Oregon Health & Science University Dralpha1-mog-35-55 treatment of traumatic brain injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US20130309229A1 (en) 2011-01-28 2013-11-21 The United States Government As Represented By The Department Of Veterans Affairs Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US9260506B2 (en) 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
JP6364352B2 (ja) 2012-01-06 2018-07-25 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
WO2015051328A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University TREATMENT OF ISCHEMIC STROKE WITH DRα1-MOG-35-55
WO2017070569A1 (en) 2015-10-23 2017-04-27 Oregon Health & Science University Compounds that bind macrophage migration inhibitory factor
US10689446B2 (en) 2016-06-22 2020-06-23 Oregon Health & Science University Recombinant CD74 polypeptides
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US20150098956A1 (en) * 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS
US20180271935A1 (en) * 2017-03-15 2018-09-27 Oregon Health & Science University Dralpha1-mog-35-55 treatment of traumatic brain injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANYA Y HUAN, ROBERTO MEZA-ROMERO, JEFFERY L MOONEY, YUAN K CHOU, DAVID M EDWARDS, CATHLEEN RICH, JASON M LINK, ARTHUR A VANDENBA: "Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity", JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, WILEY, HOBOKEN, USA, vol. 80, no. 1, 1 January 2005 (2005-01-01), Hoboken, USA, pages 2 - 12, XP001595916, ISSN: 0268-2575, DOI: 10.1002/jctb.1086 *

Also Published As

Publication number Publication date
CN113164573A (zh) 2021-07-23
JP7511551B2 (ja) 2024-07-05
JP2022504217A (ja) 2022-01-13
EP3860644A1 (en) 2021-08-11
WO2020072992A1 (en) 2020-04-09
US20210380660A1 (en) 2021-12-09
US11945855B2 (en) 2024-04-02
CN113164573B (zh) 2024-05-31
CA3114446A1 (en) 2020-04-09
KR20210071019A (ko) 2021-06-15
KR102925681B1 (ko) 2026-02-10
AU2019355062A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
Greer et al. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice
US8343500B2 (en) Peptide composition
US20150044245A1 (en) Partial mhc constructs and methods of use
AU672313B2 (en) Composition for preventing or treating a T cell mediated pathology
JP3072330B2 (ja) 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
JP2008537736A (ja) 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子
US6464978B1 (en) Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
EP0922057A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
US10316075B2 (en) Recombinant polypeptides comprising MHC class II α1 domains
AU2019355062B2 (en) Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use
EP2945966B1 (en) Peptide
US10525101B2 (en) Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
Brocke et al. Inhibition of T cell proliferation specific for acetylcholine receptor epitopes related to myasthenia gravis with antibody to T cell receptor or with competitive synthetic polymers
Vainiene et al. Natural immunodominant and experimental autoimmune encephalomyelitis‐protective determinants within the lewis rat Vβ8. 2 sequence include CDR2 and framework 3 idiotopes
AU648753C (en) Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
HK1211596B (en) Peptide
WO2002020047A2 (en) Chlamydial peptides and their mimics in demyelinating disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)